Precision's Messerschmidt and Schafer Discuss Cost of New Gene Therapies With Managed Healthcare Executive

 

In Managed Healthcare Executive, Precision Oncology’s Gerald Messerschmidt and Precision for Value’s Jeremy Schafer are tapped to provide their expert perspectives on the cost and value challenges facing the new class of CAR T-cell therapies.

To read the complete article, click here.